June 12, 2023 Sojitz Corporation (“Sojitz”) signed a memorandum of understanding with HIROTSU Bioscience Inc.(“HIROTSU”), a developer and provider of N-NOSE®, a primary cancer screening test is a revolutionary offering for early cancer detection, the WHO Foundation (“WHO Foundation”), OurCrowd, a venture capital firm and the Global Health Equity Fund (“GHEF”), a fund that invests in innovative new medical technologies to tackle health inequity to jointly conduct strategic alliances and feasibility studies for the deployment of N-NOSE® in low and middle-income countries and regions.

Read more here.